BCAS3 Antibody (N-term) Blocking Peptide

Background:
Breast cancer amplified sequence 3 (BCAS3) was identified as a gene overexpressed and amplified in breast cancer cell lines. BCAS3 expression has been shown to be regulated by estrogen receptor alpha (ER alpha) and its coregulator PELP1 (proline-, glutamic acid-, and leucine-rich protein 1). BCAS3 has also been demonstrated to act as a coactivator of ER alpha activity in breast cancer cells and associate with the histone acetyltransferase complex protein P/CAF (p300/CBP-associated factor).

Other Names:
Breast carcinoma-amplified sequence 3 {ECO:0000312|HGNC:HGNC:14347, ECO:0000312|MIM:607470}, GAOB1, BCAS3 {ECO:0000312|HGNC:HGNC:14347, ECO:0000312|MIM:607470}

Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2738a was selected from the N-term region of human BCAS3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Gene Name: BCAS3 {ECO:0000312|HGNC:HGNC:14347, ECO:0000312|MIM:607470}

Gene ID: 54828
Primary Accession: Q9H6U6
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.